Skip to Main Content

WASHINGTON — Novo Nordisk’s pledge to limit price hikes on its medicines could be more than goodwill — it could also help keep lawmakers and regulators off the drug industry’s back.

Pharma and biotech were widely seen as big winners when Donald Trump won the White House and Republicans kept control of Congress. But to cash in on that good luck, industry officials and lobbyists say, drug makers have to play their part. In other words, they’ve got to avoid headline-grabbing price hikes that force politicians to react.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED